Combination therapy using verteporfin and ranibizumab; Optimizing the timing in the cam model

Photochemistry and Photobiology

Volumn 85, Issue 6, 2009, Pages 1400-1408

  Debefve, Elodie ^a   Pegaz, Bernadette ^a   Ballini, Jean Pierre ^a   Van Den Bergh, Hubert ^a  

^a EPFL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

MONOCLONAL ANTIBODY; PORPHYRIN; RANIBIZUMAB; VERTEPORFIN;

ANIMAL; ARTICLE; CHEMICALLY INDUCED DISORDER; CHICK EMBRYO; CHORIOALLANTOIS; COMPARATIVE STUDY; DISEASE MODEL; DRUG COMBINATION; DRUG EFFECT; GRAFT OCCLUSION; HUMAN; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PHOTOCHEMOTHERAPY; TIME;

ANIMALS; ANTIBODIES, MONOCLONAL; ARTERIAL OCCLUSIVE DISEASES; CHICK EMBRYO; CHORIOALLANTOIC MEMBRANE; DISEASE MODELS, ANIMAL; DRUG THERAPY, COMBINATION; GRAFT OCCLUSION, VASCULAR; HUMANS; PHOTOCHEMOTHERAPY; PORPHYRINS; TIME FACTORS;

EID: 70449107640     PISSN: 00318655     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1751-1097.2009.00604.x     Document Type: Article

References (31)

1. Schmidt-Erfurth, U. M. C. Pruente (2007) Management of neovascular age-related macular degeneration. Prog. Retin. Eye Res. 26, 437 451.
2. Schmidt-Erfurth, U. M., G. Richard, A. Augustin, W. G. Aylward, F. Bandello, B. Corcostegui, J. Cunha-Vaz, A. Gaudric, A. Leys R. O. Schlingemann (2007) Guidance for the treatment of neovascular age-related macular degeneration. Acta Ophthalmol. Scand. 85, 486 494. (Pubitemid 47163109)
3. Schmidt-Erfurth, U., U. Schlotzer-Schrehard, C. Cursiefen, S. Michels, A. Beckendorf G. O. Naumann (2003) Influence of photodynamic therapy on expression of vascular endothelial growth factor (VEGF), VEGF receptor 3, and pigment epithelium-derived factor. Invest. Ophthalmol. Vis. Sci. 44, 4473 4480.
4. Tatar, O., A. Adam, K. Shinoda, P. Stalmans, C. Eckardt, M. Luke, K. Bartz-Schmidt S. Grisanti (2006) Expression of VEGF and PEDF in choroidal neovascular membranes following verteporfin photodynamic therapy. Am. J. Ophthalmol. 142, 95 104.
5. Tatar, O., A. Adam, K. Shinoda, E. Yoeruek, P. Szurman, S. Bopp, C. Eckardt, K. U. Bartz-Schmidt S. Grisanti (2007) Influence of vertepon photodynamic therapy on inflammation in human choroidal neovascular membranes secondary to age-related macular degeneration. Retina-J. Ret. Vit. Dis. 27, 713 723.
6. Petermeier, K., O. Tatar, W. Inhoffen, M. Voelker, B. A. Lafaut, S. Henke-Fahle, F. Gelisken, F. Ziemssen, S. Bopp, K. U. Bartz-Schmidt S. Grisanti (2006) Verteporfin photodynamic therapy induced apoptosis in choroidal neovascular membranes. Br. J. Ophthalmol. 90, 1034 1039. (Pubitemid 44140188)
7. Costa, R. A., M. E. Farah, J. A. Cardillo, D. Calucci G. A. Williams (2003) Immediate indocyanine green angiography and optical coherence tomography evaluation after photodynamic therapy for subfoveal choroidal neovascularization. Retina 23, 159 165.
8. Miller, J. W., U. Schmidt-Erfurth, M. Sickenberg, C. J. Pournaras, H. Laqua, I. Barbazetto, L. Zografos, B. Piguet, G. Donati, A. M. Lane, R. Birngruber, H. van den Berg, A. Strong, U. Manjuris, T. Gray, M. Fsadni, N. M. Bressler E. S. Gragoudas (1999) Photodynamic therapy with verteporfin for choroidal neovascularization caused by age-related macular degeneration: Results of a single treatment in a phase 1 and 2 study. Arch. Ophthalmol. 117, 1161 1173. (Pubitemid 29428825)
9. van den Bergh, H. (2001) Photodynamic therapy of age-related macular degeneration: History and principles. Semin. Ophthalmol. 16, 181 200.
10. Kaiser, P. K. (2006) Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: 5-year results of two randomized clinical trials with an open-label extension. TAP Report No. 8. Graefes Arch. Clin. Exp. Ophthalmol. 244, 1132 1142.
11. Documed S A (2009) Compendium Suisse des Médicaments. Basel, Switzerland.
12. Bradley, J., M. Ju G. S. Robinson (2007) Combination therapy for the treatment of ocular neovascularization. Angiogenesis 10, 141 148.
13. Augustin, A. J. I. Offermann (2007) Combination therapy for choroidal neovascularisation. Drugs Aging 24, 979 990.
14. Zuluaga, M. F., C. Mailhos, G. Robinson, D. T. Shima, R. Gurny N. Lange (2007) Synergies of VEGF inhibition and photodynamic therapy in the treatment of age-related macular degeneration. Invest. Ophthalmol. Vis. Sci. 48, 1767 1772.
15. Husain, D., I. Kim, D. Gauthier, A. M. Lane, M. K. Tsilimbaris, E. Ezra, E. J. Connolly, N. Michaud, E. S. Gragoudas, C. A. O'Neill, J. C. Beyer J. W. Miller (2005) Safety and efficacy of intravitreal injection of ranibizumab in combination with verteporfin PDT on experimental choroidal neovascularization in the monkey. Arch. Ophthalmol. 123, 509 516.
16. Kim, I. K., D. Husain, N. Michaud, E. Connolly, A. M. Lane, K. Durrani, A. Hafezi-Moghadam, E. S. Gragoudas, C. A. O'Neill, J. C. Beyer J. W. Miller (2006) Effect of intravitreal injection of ranibizumab in combination with verteporfin PDT on normal primate retina and choroid. Invest. Ophthalmol. Vis. Sci. 47, 357 363.
17. Heier, J. S., D. S. Boyer, T. A. Ciulla, P. J. Ferrone, J. M. Jumper, R. C. Gentile, D. Kotlovker, C. Y. Chung R. Y. Kim (2006) Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration - Year 1 results of the FOCUS study. Arch. Ophthalmol. 124, 1532 1542.
18. Augustin, A. J., S. Puls I. Offermann (2007) Triple therapy for choroidal neovascularization due to age-related macular degeneration - Verteporfin PDT, bevacimmab, and dexamethasone. Retina-J. Ret. Vit. Dis. 27, 133 140.
19. Augustin, A. J. U. Schmidt-Erfurth (2006) Verteporfin therapy combined with intravitreal triamcinolone in all types of choroidal neovascularization due to age-related macular degeneration. Ophthalmology 113, 14 22.
20. Kaiser, P. K. Registry of Visudyne AMD Therapy Writing Committee, D. S. Boyer, R. Garcia, Y. Hao, M. S. Hughes, N. M. Jabbour, P. K. Kaiser, W. Mieler, J. S. Slakter, M. Samuel, M. J. Tolentino, D. Roth, T. Sheidow, H. A. Strong (2009) Verteporfin photodynamic therapy combined with intravitreal bevacizumab for neovascular age-related macular degeneration. Ophthalmology 116 (4 747 755.
21. Lazic, R. N. Gabric (2007) Verteporfin therapy and intravitreal bevacizumab combined and alone in choroidal neovascularization due to age-related macular degeneration. Ophthalmology 114, 1179 1185.
22. Ruiz-Moreno, J. M., J. A. Montero M. A. Zarbin (2007) Photodynamic therapy and high-dose intravitreal triamcinolone to treat exudative age-related macular degeneration: 2-year outcome. Retina 27, 458 461.
23. Schadlu, R., S. M. Kymes R. S. Apte (2007) Combined photodynamic therapy and intravitreal triamcinolone for neovascular age-related macular degeneration: Effect of initial visual acuity on treatment response. Graefes Arch. Clin. Exp. Ophthalmol. 245, 1667 1672.
24. Smith, B. T., M. S. Dhalla, G. K. Shah, K. J. Blinder, E. H. Ryan Jr. R. A. Mittra (2008) Intravitreal injection of bevacizumab combined with verteporfin photodynamic therapy for choroidal neovascularization in age-related macular degeneration. Retina 28, 675 681.
25. Lange, N., J. P. Ballini, G. Wagnieres H. van den Bergh (2001) A new drug-screening procedure for photosensitizing agents used in photodynamic therapy for CNV. Invest. Ophthalmol. Vis. Sci. 42, 38 46.
26. Debefve, E., B. Pegaz, J. P. Ballini, Y. N. Konan H. van den Bergh (2007) Combination therapy using aspirin-enhanced photodynamic selective drug delivery. Vascul Pharmacol 46, 171 180.
27. Debefve, E., B. Pegaz, H. van den Bergh, G. Wagnieres, N. Lange J. P. Ballini (2008) Video monitoring of neovessel occlusion induced by photodynamic therapy with verteporfin (Visudyne), in the CAM model. Angiogenesis 11, 235 243.
28. Vargas, A., M. Zeisser-Labouebe, N. Lange, R. Gurny F. Delie (2007) The chick embryo and its chorioallantoic membrane (CAM) for the in vivo evaluation of drug delivery systems. Adv. Drug Deliv. Rev. 59, 1162 1176.
29. Schmidt-Erfurth, U. M., P. Gabel, T. Hohman PROTECT Study Group (2006) Preliminary results from an open-label, multicenter, phase II study assessing the effects of same-day administration of ranibizumab (Lucentis(TM)) and verteporfin PDT (PROTECT Study). Invest. Ophthalmol. Vis. Sci., 47, E-Abstract 2960.
30. Kaiser, P. K. (2007) Verteporfin photodynamic therapy and anti-angiogenic drugs: Potential for combination therapy in exudative age-related macular degeneration. Curr. Med. Res. Opin. 23, 477 487.
31. Uehara, M., T. Inokuchi, K. Sano W. ZuoLin (2001) Expression of vascular endothelial growth factor in mouse tumours subjected to photodynamic therapy. Eur. J. Cancer 37, 2111 2115.